Nicholas Vincent is a passionate environmentalist and freelance writer. He is deeply committed to promoting... Nicholas Vincent is a passionate environmentalist and freelance writer. He is deeply committed to promoting sustainability and finding solutions to the most pressing environmental challenges of our time. Read more about Nicholas Vincent Read More
Want to reach our audience?
A breakthrough treatment has allegedly cured a 21-year-old man’s sickle cell anemia—but its $3.1 million price tag puts it far out of reach for most patients. Lyfgenia, a gene therapy developed by Bluebird Bio, could transform countless lives. But unless the price is dramatically lowered, this revolutionary medicine will remain a luxury for the wealthy, not a lifeline for the many.
Sickle cell disease, affecting mainly Black and Hispanic communities, causes intense pain, organ damage, and early death. The cure exists. Yet, millions still suffer because they can’t afford it.
This is a matter of justice, not just science. Sign the petition now to demand that Bluebird Bio slash the price of Lyfgenia. Urge the FDA to ensure this treatment is accessible to all—not just the privileged few.
Sign the petition now. Lives are on the line.
Sign These Urgent Petitions!
Get your favorite articles delivered right to your inbox! Sign up for daily news from OneGreenPlanet.
Keep One Green Planet independent — chip in what you can, or become a member and get ad-free browsing, a voice in our community, and the good feeling of fueling a sustainable, healthier, and kinder world.
Comments: